Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.

Fractyl Health, Inc. Common Stock

Fractyl Health is a leader in creating innovative therapies to address the root cause of type 2 diabetes. 

We were founded based on groundbreaking research and biological insights showing the key role of the intestine in metabolic control. Our therapies are uniquely designed to target and control this controller for the treatment of metabolic disease.

Our lead program, Revita DMR, is a first-in-class procedural therapy that is now in late-stage clinical trials for the treatment of type 2 diabetes.  

Our team is made up of passionate innovators at the intersection of biology and technology, working to deliver better real-world outcomes for people with metabolic disease. 

Fractyl is located in Lexington, Mass.  


General Catalyst

Bessemer Venture Partners

Catalio Capital Management

CDIB Ventures

Taiwania Capital Management Corporation

True Ventures

Mithril Capital Management

Google Ventures

Domain Associates

Emergent Medical Partners

Population Health Partners

M28 Capital

Maverick Capital

Fractyl Health

Fractyl Health announces new pooled analysis from our Revita® clinical studies demonstrating initial weight loss and sustained weight maintenance without weight regain through at least one-year post-Revita procedure. These new results, in over 100 human subjects from our controlled clinical studies, demonstrate that a single treatment with Revita can potentially enable sustained weight maintenance in people who are at risk of weight gain. https://lnkd.in/dKEAWd_r

We are thrilled to have presented preclinical findings from our Rejuva® gene therapy platform at the World Congress Insulin Resistance Diabetes and Cardiovascular Disease 2023 Annual Meeting. The oral presentation, titled “Single-dose GLP-1-based Pancreatic Gene Therapy Maintains Weight Loss After Semaglutide Withdrawal in a Murine Model of Obesity,” highlighted the promising implications of the Rejuva platform in providing a durable therapeutic solution for obesity with a GLP-1-based pancreatic gene therapy candidate (GLP-1 PGTx) designed to target the pancreas to provide long-term metabolic benefits from a single administration. #WCIRDC23 #T2D #obesity 

https://lnkd.in/eAKF-d_Z
maintained-weight-loss-after-semaglutide-withdrawal-in-a-murine-model-of-obesity/

*The Rejuva platform is in preclinical development and has not yet been evaluated by regulatory agencies for investigational or commercial use. 

We are excited to announce the expansion of an academic-industry scientific partnership charged with advancing research on the role of the gut and pancreas in metabolic disease. The new research, to be led by Professor Randy Seeley, Ph.D., at Michigan Medicine, is intended to explore the mechanistic rationale underlying the use of local pancreatic gene therapy to produce targeted treatment options that address, and hopefully remit, metabolic diseases. #T2D #obesity #type2diabetes #biotech #research #DiabetesAwarenessMonth https://lnkd.in/eEmyB_pe  

*The Rejuva platform is in preclinical development and has not yet been evaluated by regulatory agencies for investigational or commercial use. 

Today at #EASD2023, Dr. Harith Rajagopalan, Fractyl Health’s CEO, presented “Pancreatic Gene Therapy Durably Improves Glycemia and Delays Disease Progression in a Murine Model of Type 2 Diabetes.” 

Emphasizing new proof-of-concept data for Fractyl Health’s Rejuva® pancreatic gene therapy platform*, the presentation highlighted the promising implications of the Rejuva platform in potentially reshaping the treatment landscape for T2D and obesity with a GLP-1 based pancreatic gene therapy candidate (GLP-1 PGTx) designed to target the pancreas to provide long-term metabolic benefits from a single administration. The data presented corroborates the fundamental hypothesis that local delivery of a GLP-1 PGTx, driven by the insulin promoter, can potentially provide sustained weight loss after a single administration in obesity.  
 
The goal of Fractyl’s Rejuva platform is to develop gene therapy candidates that can durably change the trajectory of both obesity and T2D, and today’s results further consolidate preclinical proof-of-concept data for the viability of this approach. https://lnkd.in/ehUDdC6C #T2D #obesity #biotech #health #diabetes  
 
*The Rejuva platform is in preclinical development and has not yet been evaluated by regulatory agencies for investigational or commercial use.

	Dec '21	Dec '22	Dec '23
net income	-38.73M -	-46.45M 19.93%	-77.09M 65.95%
depreciation and amortization	676K -	452K 33.14%	286K 36.73%
deferred income tax
stock based compensation	2.09M -	3.14M 50.07%	4.30M 36.90%
change in working capital	1.71M -	-1.24M 172.59%	989K 179.63%
accounts receivables			-22K -
inventory			-73K -
accounts payables	666K -	10K 98.50%	-427K 4,370%
other working capital	1.71M -	-1.24M 172.59%	1.51M 221.66%
other non cash items	4.24M -	1.90M 55.07%	34.09M 1,690.28%
net cash provided by operating activities	-33.46M -	-46.24M 38.20%	-42.82M 7.40%
investments in property plant and equipment	-51K -	-56K 9.80%	-359K 541.07%
acquisitions net
purchases of investments
sales maturities of investments
other investing activites
net cash used for investing activites	-51K -	-56K 9.80%	-359K 541.07%
debt repayment	-7K -	-4.03M 57,457.14%	-27.95M 593.67%
common stock issued	99.89M -	321K 99.68%	-511K 259.19%
common stock repurchased
dividends paid
other financing activites	99.89M -	321K 99.68%	-963K 400%
net cash used provided by financing activities	99.88M -	4.35M 95.64%	27.44M 530.74%
effect of forex changes on cash
net change in cash	66.37M -	-46.20M 169.62%	-15.74M 65.92%
cash at beginning of period	29.11M -	95.47M 228.01%	49.27M 48.39%
cash at end of period	95.47M -	49.27M 48.39%	33.52M 31.96%
operating cash flow	-33.46M -	-46.24M 38.20%	-42.82M 7.40%
capital expenditure	-51K -	-56K 9.80%	-359K 541.07%
free cash flow	-33.51M -	-46.30M 38.15%	-43.18M 6.73%

COM:FRACTYL

Fractyl Laboratories

Last Close

3.58

30/08 20:00

Market Cap

214.10M

Beta: -

Volume Today

336.81K

Avg: -

Preview